Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma

Jeffrey L. Wolf; David Siegel; Hartmut Goldschmidt; Katharine Hazell; Priscille M. Bourquelot; Bourras R. Bengoudifa; Jeffrey Matous; Ravi Vij; Margarida De Magalhaes-Silverman; Rafat Abonour; Kenneth C. Anderson; Sagar Lonial

doi:10.3109/10428194.2012.661175

Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma

Jeffrey L. Wolf
, David Siegel
, Hartmut Goldschmidt
, Katharine Hazell
, Priscille M. Bourquelot
, Bourras R. Bengoudifa
, Jeffrey Matous
, Ravi Vij
, Margarida De Magalhaes-Silverman
, Rafat Abonour
, Kenneth C. Anderson
, Sagar Lonial

School of Medicine

University of California at San Francisco
Heidelberg University
Novartis
Colorado Blood Cancer Institute
Washington University St. Louis
University of Iowa
Indiana University Bloomington
Dana-Farber Cancer Institute
Emory University

Research output: Contribution to journal › Letter › peer-review

117 Scopus citations

Original language	English
Pages (from-to)	1820-1823
Number of pages	4
Journal	Leukemia and Lymphoma
Volume	53
Issue number	9
DOIs	https://doi.org/10.3109/10428194.2012.661175
State	Published - Sep 2012

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.3109/10428194.2012.661175

Cite this

Wolf, J. L., Siegel, D., Goldschmidt, H., Hazell, K., Bourquelot, P. M., Bengoudifa, B. R., Matous, J., Vij, R., De Magalhaes-Silverman, M., Abonour, R., Anderson, K. C., & Lonial, S. (2012). Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma. Leukemia and Lymphoma, 53(9), 1820-1823. https://doi.org/10.3109/10428194.2012.661175

@article{2e64480fec914d2c81fde1e01cb07e87,

title = "Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma",

author = "Wolf, \{Jeffrey L.\} and David Siegel and Hartmut Goldschmidt and Katharine Hazell and Bourquelot, \{Priscille M.\} and Bengoudifa, \{Bourras R.\} and Jeffrey Matous and Ravi Vij and \{De Magalhaes-Silverman\}, Margarida and Rafat Abonour and Anderson, \{Kenneth C.\} and Sagar Lonial",

year = "2012",

month = sep,

doi = "10.3109/10428194.2012.661175",

language = "English",

volume = "53",

pages = "1820--1823",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Taylor and Francis Ltd.",

number = "9",

}

Wolf, JL, Siegel, D, Goldschmidt, H, Hazell, K, Bourquelot, PM, Bengoudifa, BR, Matous, J, Vij, R, De Magalhaes-Silverman, M, Abonour, R, Anderson, KC & Lonial, S 2012, 'Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma', Leukemia and Lymphoma, vol. 53, no. 9, pp. 1820-1823. https://doi.org/10.3109/10428194.2012.661175

TY - JOUR

T1 - Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma

AU - Wolf, Jeffrey L.

AU - Siegel, David

AU - Goldschmidt, Hartmut

AU - Hazell, Katharine

AU - Bourquelot, Priscille M.

AU - Bengoudifa, Bourras R.

AU - Matous, Jeffrey

AU - Vij, Ravi

AU - De Magalhaes-Silverman, Margarida

AU - Abonour, Rafat

AU - Anderson, Kenneth C.

AU - Lonial, Sagar

PY - 2012/9

Y1 - 2012/9

UR - https://www.scopus.com/pages/publications/84862878624

U2 - 10.3109/10428194.2012.661175

DO - 10.3109/10428194.2012.661175

M3 - Letter

C2 - 22288662

AN - SCOPUS:84862878624

SN - 1042-8194

VL - 53

SP - 1820

EP - 1823

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

IS - 9

ER -

Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma

UN SDGs

Access to Document

Other files and links

Cite this